bevacizumab + oxaliplatin + levofolinate calcium + fluorouracil

**bevacizumab + oxaliplatin + levofolinate calcium + fluorouracil** is a four-drug combination regimen primarily used for the treatment of metastatic colorectal cancer. It consists of: - **bevacizumab:** a monoclonal antibody that binds vascular endothelial growth factor (VEGF), inhibiting angiogenesis and tumor blood vessel formation. - **oxaliplatin:** a platinum-based cytotoxic agent that interferes with DNA replication and transcription in cancer cells through DNA crosslinking. - **levofolinate calcium (folinic acid, leucovorin):** a reduced folate that enhances the cytotoxic effects of fluorouracil by stabilizing the binding of fluorouracil's metabolites to the target enzyme thymidylate synthase. - **fluorouracil (5-FU):** an antimetabolite that inhibits DNA synthesis by blocking thymidylate synthase, leading to cytotoxicity in rapidly dividing cells. This regimen is administered intravenously and is commonly referred to as FOLFOX plus bevacizumab[1][2][4]. It is a frontline therapy for metastatic colorectal cancer, where bevacizumab enhances the efficacy of the core FOLFOX chemotherapy, resulting in increased response rates and survival[1][2][4].

Other names

FOLFOX + bevacizumabbevacizumab-FOLFOXbevacizumab + FOLFOXbevacizumab + oxaliplatin + folinic acid + fluorouracil